FY2026 EPS Estimates for Pfizer Reduced by Erste Group Bank

Posted by Geri Gentry on Jul 1st, 2026

Pfizer Inc. (NYSE:PFE – Free Report) – Equities researchers at Erste Group Bank reduced their FY2026 earnings per share estimates for Pfizer in a note issued to investors on Thursday, June 25th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will earn $2.95 per share for the year, down from their previous forecast of $2.96. The consensus estimate for Pfizer’s current full-year earnings is $2.99 per share.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

Several other brokerages have also weighed in on PFE. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Morgan Stanley lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Citigroup raised their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, Wolfe Research restated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.82.

View Our Latest Stock Report on PFE

Pfizer Trading Down 1.2%

Shares of Pfizer stock opened at $24.08 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The business has a fifty day simple moving average of $25.81 and a two-hundred day simple moving average of $26.27. Pfizer has a 1 year low of $23.11 and a 1 year high of $28.75. The company has a market capitalization of $137.23 billion, a price-to-earnings ratio of 18.38 and a beta of 0.34.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vermillion Wealth Management Inc. raised its position in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 382 shares in the last quarter. Triad Wealth Partners LLC grew its position in Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares in the last quarter. Eagle Capital Management LLC grew its position in Pfizer by 0.3% during the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares in the last quarter. ETF Store Inc. increased its stake in Pfizer by 3.8% during the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares during the period. Finally, Delta Financial Advisors LLC raised its holdings in Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer’s GLP-1 drug Ecnoglutide cleared a preliminary review for possible inclusion in China’s basic medical insurance drug catalogue, a potentially meaningful commercialization step for its obesity/diabetes pipeline. Article Title
Positive Sentiment: Investor commentary continues to frame Pfizer as a value and income stock, citing its high dividend yield and low valuation metrics, which may be attracting bargain hunters. Article Title
Positive Sentiment: Pfizer also signed a SuperHuman platform license agreement with Distributed Bio, suggesting continued dealmaking to strengthen its drug-development pipeline. Article Title
Neutral Sentiment: Multiple market recaps said Pfizer traded lower while the market improved, but the stock still outperformed some competitors, indicating the move may have been more about sector sentiment than company-specific news. Article Title
Neutral Sentiment: Pfizer completed a real-world COVID-19 vaccine study and investors are awaiting data release, which could matter for sentiment but is not yet a confirmed catalyst. Article Title
Negative Sentiment: Bearish commentary continues to focus on fading COVID franchise sales, with one article noting sharp declines in Comirnaty and Paxlovid revenue, reinforcing concerns about Pfizer’s near-term growth outlook. Article Title

About Pfizer

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.